Youli Zu

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov et al. · Blood · 2013 · 679 citations · Full text

Medicine, Cancer Biology, Oncology +15

Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy

Hongguang Sun, Xun Zhu, Patrick Lu et al. · Molecular Therapy — Nucleic Acids · 2014 · 530 citations · Full text

Medicine, Molecular Biology, Oncology +17

Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins

Catherine M. Bollard, Stephen Gottschalk, Vicky Torrano et al. · Journal of Clinical Oncology · 2013 · 502 citations

Life Sciences, Immunology, Oncology +17

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study

Zijun Y. Xu‐Monette, Lin Wu, Carlo Visco et al. · Blood · 2012 · 391 citations · Full text

Medicine, Hematology, Oncology +14

Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study

Carlo Visco, Y Li, Zijun Y. Xu‐Monette et al. · Leukemia · 2012 · 362 citations

Medicine, Molecular Biology, Oncology +17